JP5090171B2 - 真性赤血球増加症に関与するｊａｋ２の変異の識別方法 - Google Patents

真性赤血球増加症に関与するｊａｋ２の変異の識別方法 Download PDF

Info

Publication number
JP5090171B2
JP5090171B2 JP2007538421A JP2007538421A JP5090171B2 JP 5090171 B2 JP5090171 B2 JP 5090171B2 JP 2007538421 A JP2007538421 A JP 2007538421A JP 2007538421 A JP2007538421 A JP 2007538421A JP 5090171 B2 JP5090171 B2 JP 5090171B2
Authority
JP
Japan
Prior art keywords
jak2
mutation
cells
seq
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2007538421A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008517613A5 (enExample
JP2008517613A (ja
Inventor
ヴァンシャンケ、ウィリアム
ウーゴ、ヴァレリー
ジャム、クローエ
クェディック、ジャン−ピエール レ
カザデバル、ニコル
Original Assignee
アシスタンス ピュブリック−オピト ドゥ パリ
アンスティテュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル（インセルム）
アンスティテュ ギュスターブ−ルシ
ユニヴェルシテ ドゥ ヴェルサイユ−サン クァンタン アン イヴェリーヌ
ユニヴェルシテ パリ−シュド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34953071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5090171(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アシスタンス ピュブリック−オピト ドゥ パリ, アンスティテュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル（インセルム）, アンスティテュ ギュスターブ−ルシ, ユニヴェルシテ ドゥ ヴェルサイユ−サン クァンタン アン イヴェリーヌ, ユニヴェルシテ パリ−シュド filed Critical アシスタンス ピュブリック−オピト ドゥ パリ
Publication of JP2008517613A publication Critical patent/JP2008517613A/ja
Publication of JP2008517613A5 publication Critical patent/JP2008517613A5/ja
Application granted granted Critical
Publication of JP5090171B2 publication Critical patent/JP5090171B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
JP2007538421A 2004-10-27 2005-10-26 真性赤血球増加症に関与するｊａｋ２の変異の識別方法 Expired - Lifetime JP5090171B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0411480 2004-10-27
FR0411480A FR2877013A1 (fr) 2004-10-27 2004-10-27 Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
PCT/EP2005/055586 WO2006045827A1 (fr) 2004-10-27 2005-10-26 Identification d'une mutation de jak2 impliquée dans la polyglobulie de vaquez

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009155912A Division JP5290884B2 (ja) 2004-10-27 2009-06-30 真性赤血球増加症に関与するｊａｋ２の変異の識別方法

Publications (3)

Publication Number Publication Date
JP2008517613A JP2008517613A (ja) 2008-05-29
JP2008517613A5 JP2008517613A5 (enExample) 2009-03-05
JP5090171B2 true JP5090171B2 (ja) 2012-12-05

Family

ID=34953071

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007538421A Expired - Lifetime JP5090171B2 (ja) 2004-10-27 2005-10-26 真性赤血球増加症に関与するｊａｋ２の変異の識別方法
JP2009155912A Expired - Lifetime JP5290884B2 (ja) 2004-10-27 2009-06-30 真性赤血球増加症に関与するｊａｋ２の変異の識別方法
JP2013003374A Expired - Lifetime JP6103691B2 (ja) 2004-10-27 2013-01-11 真性赤血球増加症に関与するｊａｋ２の変異の識別方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009155912A Expired - Lifetime JP5290884B2 (ja) 2004-10-27 2009-06-30 真性赤血球増加症に関与するｊａｋ２の変異の識別方法
JP2013003374A Expired - Lifetime JP6103691B2 (ja) 2004-10-27 2013-01-11 真性赤血球増加症に関与するｊａｋ２の変異の識別方法

Country Status (20)

Country Link
US (9) US7781199B2 (enExample)
EP (2) EP1895000A1 (enExample)
JP (3) JP5090171B2 (enExample)
KR (1) KR101203003B1 (enExample)
CN (1) CN101072870B (enExample)
AT (1) ATE382082T1 (enExample)
AU (1) AU2005298636B2 (enExample)
BR (1) BRPI0517398B8 (enExample)
CA (3) CA2647086C (enExample)
DE (1) DE602005004008T2 (enExample)
DK (1) DK1692281T3 (enExample)
ES (1) ES2296229T3 (enExample)
FR (1) FR2877013A1 (enExample)
IL (1) IL182761A0 (enExample)
MX (1) MX2007005174A (enExample)
PL (1) PL1692281T3 (enExample)
PT (1) PT1692281E (enExample)
SI (1) SI1692281T1 (enExample)
WO (1) WO2006045827A1 (enExample)
ZA (1) ZA200703433B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013135673A (ja) * 2004-10-27 2013-07-11 Assistance Publique-Hopitaux De Paris 真性赤血球増加症に関与するｊａｋ２の変異の識別方法

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100497657C (zh) * 2006-09-27 2009-06-10 北京大学人民医院 检测JAK2V617F突变的方法及其专用引物与TaqMan-MGB探针
US20080153097A1 (en) * 2006-11-15 2008-06-26 Eragen Biosciences, Inc. Methods and kits for detecting jak2 nucleic acid
US8367078B2 (en) * 2007-06-06 2013-02-05 University Of Florida Research Foundation, Inc. Kinase inhibitor compounds
EP2119796B1 (en) * 2007-07-13 2014-01-15 ARKRAY, Inc. Probe for detecting mutation in jak2 gene and use thereof
GB0820631D0 (en) * 2008-11-11 2008-12-17 London School Hygiene & Tropical Medicine Vectors
EP2272978B1 (en) 2009-07-10 2012-04-18 Biotrin International Limited Highly sensitive rapid isothermal method for the detection of point mutations and SNPs
WO2011067373A1 (fr) * 2009-12-04 2011-06-09 Assistance Publique - Hopitaux De Paris Methode de detection d'une polyglobulie chez un chien
CA2789186A1 (en) * 2010-02-10 2011-08-18 Genon Biotechnologies Oy Dual activity kinase domains and uses thereof
US20120021413A1 (en) * 2010-04-30 2012-01-26 Arkray, Inc. Method for Detecting Mutation in Exon 12 of JAK2 Gene, and Nucleic Acid Probe and Kit Therefor
JP6076901B2 (ja) * 2010-07-16 2017-02-15 スティヒティング フェーユーエムセー 被験者の血液サンプル中の疾患マーカーの存在の分析方法
SG193539A1 (en) 2011-03-18 2013-10-30 Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patientenzorg A method of analysing a blood sample of a subject for the presence of a disease marker
JP2013017395A (ja) * 2011-07-07 2013-01-31 Toyobo Co Ltd 骨髄増殖性疾患に関する遺伝子変異を検出するためのプローブおよび該プローブを用いた遺伝子変異の検出方法
GB201116876D0 (en) * 2011-09-30 2011-11-16 Epistem Ltd Mutational analysis of JAK2
CN103243153B (zh) * 2012-02-10 2014-11-05 复旦大学附属华山医院 Jak2 v617f突变的检测应用
WO2014068072A1 (en) 2012-10-31 2014-05-08 Institut Gustave-Roussy Identification, assessment and therapy of essential thrombocythemia with resistance to jak2 inhibitors
US9523084B2 (en) 2012-11-08 2016-12-20 Centre National De La Recherche Scientifique (Cnrs) Phosphodeoxyribosyl transferase mutant enzymes and uses thereof
CA2890658A1 (en) 2012-11-09 2014-05-15 The Johns Hopkins University A genetic assay to determine prognosis in polycythemia vera patients
PT3456333T (pt) 2012-12-07 2020-06-01 Geron Corp Utilização do inibidor de telomerase imetelstate para o tratamento de síndrome mielodisplásica
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
SG11201509556TA (en) 2013-05-16 2015-12-30 Mobelisk Llc Modular tablet case
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
WO2016168612A1 (en) * 2015-04-15 2016-10-20 Promedior, Inc. Methods for treating myeloproliferative disorders
US10519509B2 (en) 2015-04-23 2019-12-31 Quest Diagnostics Investments Incorporated Methods and compositions for the detection of CALR mutations in myeloproliferative diseases
WO2017024171A1 (en) * 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
CN105441573A (zh) * 2016-01-11 2016-03-30 武汉海吉力生物科技有限公司 用于检测人类jak2基因v617f突变的引物、探针及试剂盒
CN109803674A (zh) * 2016-06-10 2019-05-24 Io生物技术公司 Calr和jak2疫苗组合物
EP3658156B1 (en) 2017-07-28 2026-03-25 Geron Corporation Telomerase inhibitor for use in treating a myelodysplastic syndrome
CN113631719A (zh) 2018-11-29 2021-11-09 美国杰龙生物医药公司 治疗骨髓增生异常综合征的方法
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
IL299612A (en) 2020-07-02 2023-03-01 Incyte Corp Tricyclic urea compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
CA3211748A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
IL315647A (en) 2022-03-17 2024-11-01 Incyte Corp Tricyclic urea compounds as Jak2 and 617f inhibitors
WO2026136827A1 (en) * 2024-12-20 2026-06-25 Incyte Corporation Treatment of clonal hematopoietic disorders using kinase inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US5728536A (en) * 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
WO1995011995A1 (en) 1993-10-26 1995-05-04 Affymax Technologies N.V. Arrays of nucleic acid probes on biological chips
US5753441A (en) * 1994-08-12 1998-05-19 Myriad Genetics, Inc. 170-linked breast and ovarian cancer susceptibility gene
US5747282A (en) * 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
WO1997003358A1 (en) * 1995-07-07 1997-01-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method of identifying inhibitors of the jak-stat signal transduction pathway
US5914393A (en) * 1995-12-05 1999-06-22 Incyte Pharmaceuticals, Inc. Human Jak2 kinase
FI104718B (fi) * 1998-06-18 2000-03-31 Orion Yhtymae Oyj [[4-(2-atsido-3-metyyli-5-oksotetrahydrofuran-2-yyli)fenyyli]hydratsono]propaanidinitriili käytettäväksi referenssiaineena levosimendaanierien analyysissä
US6821724B1 (en) * 1998-09-17 2004-11-23 Affymetrix, Inc. Methods of genetic analysis using nucleic acid arrays
EP1056889B1 (en) 1998-09-25 2007-06-27 Massachusetts Institute Of Technology Methods related to genotyping and dna analysis
WO2001079555A2 (en) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
IL153426A0 (en) * 2000-06-30 2003-07-06 Pfizer Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies
US20030012788A1 (en) * 2000-07-27 2003-01-16 Jean-Christophe Renauld Method for influencing kinase pathways with IL-22
US20020090622A1 (en) 2000-08-23 2002-07-11 Monisola Adeokun Chemical compounds
US20050235375A1 (en) * 2001-06-22 2005-10-20 Wenqiong Chen Transcription factors of cereals
AU2003299467A1 (en) 2002-05-03 2004-08-10 Gene Logic, Inc. Canine gene microarrays
CA2491637A1 (en) * 2002-07-03 2004-01-15 The Trustees Of Columbia University In The City Of New York Methods for identifying modulators of mda-7 mediated apoptosis
US7537891B2 (en) * 2002-08-27 2009-05-26 Bristol-Myers Squibb Company Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells
EP1572957A4 (en) * 2002-08-27 2007-10-10 Bristol Myers Squibb Pharma Co IDENTIFICATION OF POLYNUCLEOTIDES FOR PREDICTING THE ACTIVITY OF COMPOUNDS INTERACTING WITH AND / OR MODULATING TYROSINE KINASE PROTEINS AND / OR TYROSINE KINASE PROTEIN PATHWAYS IN MAMMARY CELLS
US20060019284A1 (en) * 2004-06-30 2006-01-26 Fei Huang Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in lung cancer cells
FR2877013A1 (fr) * 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US7514229B2 (en) * 2005-09-29 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and evaluating treatment of blood disorders
US20070248961A1 (en) * 2006-04-20 2007-10-25 Maher Albitar Methods for detecting mutations in JAK2 nucleic acid
EP2525651A4 (en) * 2010-01-22 2013-12-11 Chromatin Inc NEW CENTROMERE AND METHOD FOR THEIR USE

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013135673A (ja) * 2004-10-27 2013-07-11 Assistance Publique-Hopitaux De Paris 真性赤血球増加症に関与するｊａｋ２の変異の識別方法

Also Published As

Publication number Publication date
PT1692281E (pt) 2008-02-06
US7429456B2 (en) 2008-09-30
US8637235B2 (en) 2014-01-28
DE602005004008T2 (de) 2009-02-12
JP2009278982A (ja) 2009-12-03
BRPI0517398B1 (pt) 2021-03-02
US20190323007A1 (en) 2019-10-24
ES2296229T3 (es) 2008-04-16
HK1094974A1 (zh) 2007-04-20
DK1692281T3 (da) 2008-05-13
JP6103691B2 (ja) 2017-03-29
IL182761A0 (en) 2007-07-24
MX2007005174A (es) 2007-10-10
EP1692281B8 (fr) 2008-02-13
KR20070104338A (ko) 2007-10-25
US20150051263A2 (en) 2015-02-19
AU2005298636A1 (en) 2006-05-04
US20080076135A1 (en) 2008-03-27
JP5290884B2 (ja) 2013-09-18
CA2647086C (fr) 2012-09-18
US10364430B2 (en) 2019-07-30
US20090162849A1 (en) 2009-06-25
EP1692281A1 (fr) 2006-08-23
EP1895000A1 (fr) 2008-03-05
US11162100B2 (en) 2021-11-02
ZA200703433B (en) 2008-08-27
BRPI0517398B8 (pt) 2021-05-25
US20220042016A1 (en) 2022-02-10
AU2005298636B2 (en) 2009-11-26
US7781199B2 (en) 2010-08-24
JP2008517613A (ja) 2008-05-29
JP2013135673A (ja) 2013-07-11
US20060288432A1 (en) 2006-12-21
CN101072870A (zh) 2007-11-14
FR2877013A1 (fr) 2006-04-28
US20130189683A1 (en) 2013-07-25
US20200140863A1 (en) 2020-05-07
US8466338B2 (en) 2013-06-18
PL1692281T3 (pl) 2008-06-30
US8852931B2 (en) 2014-10-07
US10563200B2 (en) 2020-02-18
EP1692281B1 (fr) 2007-12-26
CA2754028A1 (fr) 2006-05-04
SI1692281T1 (sl) 2008-04-30
DE602005004008D1 (de) 2008-02-07
ATE382082T1 (de) 2008-01-15
KR101203003B1 (ko) 2012-11-21
CA2585062C (fr) 2012-11-20
US20140249204A1 (en) 2014-09-04
CA2585062A1 (fr) 2006-05-04
BRPI0517398A (pt) 2008-10-14
US20120066776A1 (en) 2012-03-15
WO2006045827A1 (fr) 2006-05-04
CA2647086A1 (fr) 2006-05-04
CN101072870B (zh) 2013-01-30

Similar Documents

Publication Publication Date Title
JP6103691B2 (ja) 真性赤血球増加症に関与するｊａｋ２の変異の識別方法
US9458508B2 (en) Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
TWI518325B (zh) 對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
HK1114406A (en) Identification of a jak2 mutation involved in polycythaemia vera
Class et al. Patent application title: IDENTIFICATION OF A JAK2 MUTATION INVOLVED IN VAQUEZ POLYGLOBULIA Inventors: William Vainchenker (Paris, FR) Assistance Publique Hopitaux De Paris (Paris, FR) Igr&d Sa (Villejuif Cedex, FR) Valerie Ugo (Paris, FR) James Chloe (Montrouge, FR) Jean-Pierre Le Couedic (Champs Sur Marne, FR) Institut Gustave-Roussy (Villejuif, FR) Nicole Casadevall (Paris, FR) Universite De Versailles-St Quentin En Yvelines (Versailles, FR) Universite Paris-Sud (Orsay, FR) Assignees: Assistance Publique-Hopitaux De Paris IGR&D SA Universite Paris-Sud INSTITUT GUSTAVE ROUSSY UNIVERSITE DE VERSAILLES ST QUENTIN EN YVELINES INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
HK1094974B (en) Identification of a jak2 mutation in polycythemia vera
US20120207758A1 (en) CD22 Exon 12 Deletion Mutants
WO2016139541A1 (en) Methods of characterizing e-syt2 inhibitors, e-syt2 inhibitors, and methods of use

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090113

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20090113

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20090205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090630

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090811

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091203

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20091218

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120726

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120912

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150921

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5090171

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term